Skip to main content
NVDA-2.10%AAPL+2.69%GOOGL+0.24%MSFT+0.56%AMZN+0.12%TSM-0.81%SPCX+2.02%AVGO+0.03%META-0.22%TSLA-0.47%SKHY-3.57%MU-4.31%BRK-B-0.24%LLY+0.25%JPM-0.60%WMT+0.20%AMD-2.67%V-0.09%XOM+0.78%ASMLa-1.66%JNJ-0.19%INTC-4.47%MA-0.42%0700.HK-1.94%1398.HK+0.79%ORCL-2.97%ABBV+0.61%BAC-0.65%CSCO-0.91%CVX0.00%COST-0.01%KO+0.78%LRCX-4.62%CAT-1.46%AP2d-1.55%0005.HK-0.78%AMAT-2.16%UNH-0.23%HSBA.L-1.30%DELL-3.64%PG-0.05%MS-0.60%GE-0.47%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.05%HD-1.35%0939.HK+1.66%GS-0.76%NZDJPY-2.49%AUDJPY-1.75%CHFJPY-1.55%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.32%USDJPY-1.27%NZDUSD-1.25%EURJPY-1.20%GBPJPY-1.18%CADJPY-1.10%NZDCHF-0.97%USDZAR+0.89%USDNOK+0.82%EURZAR+0.79%USDSEK+0.77%AUDNZD+0.77%GBPZAR+0.74%EURNOK+0.72%AUDCAD-0.68%EURSEK+0.67%AUDDKK-0.60%CHFNOK+0.59%EURAUD+0.56%GBPAUD+0.55%USDTHB+0.54%CHFSEK+0.53%AUDUSD-0.49%AUDSGD-0.48%CADCHF+0.43%USDMXN+0.43%GBPTRY+0.41%NOKJPY-0.35%USDPLN+0.35%GBPCHF+0.35%EURCHF+0.34%GBPHKD+0.32%NZDSGD-0.31%USDCHF+0.29%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.25%USDSGD+0.21%AUDCHF-0.21%USDILS+0.16%USDCAD-0.15%AUDNOK+0.12%NZDMXN-0.12%PLNJPY+0.12%EURSGD+0.11%EURHKD-0.11%USDTRY+0.11%GBPCAD-0.10%USDDKK+0.10%EURCAD-0.10%EURCZK-0.08%USDCNH+0.08%GBPUSD+0.08%EURUSD+0.06%GBPSGD+0.06%USDCOP-0.04%CHFSGD-0.02%USDHKD+0.01%EURGBP+0.01%EURDKK0.00%EURCNH0.00%XPTUSD-5.22%UKOIL+4.94%USOIL+4.58%HG1-4.54%GAGUSD-4.20%XAGUSD-4.20%GAUUSD-0.80%XAUUSD-0.80%COTTON+0.67%S1+0.49%XNGUSD+0.48%COFFEE-0.46%BTCUSD-1.38%ETHUSD-0.57%USDTUSD-0.02%XRPUSD-2.75%SOLUSD-1.67%TRXUSDT+0.03%ZECUSDT-8.60%DOGEUSD-2.91%XMRUSDT-0.86%LINKUSD-1.49%XLMUSD-1.82%BCHUSDT-9.83%LTCUSD-1.56%UNIUSD-2.61%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.76%TAOUSDT-4.65%AAVEUSD-2.57%DOTUSDT-2.67%ICPUSDT-1.78%ONDOUSDT-3.23%WLDUSDT-2.67%ATOMUSDT-3.51%ARBUSDT-0.87%JUPUSDT-4.25%INJUSDT-3.68%STXUSDT-4.16%FETUSDT-3.86%TIAUSDT-1.65%PYTHUSDT-1.33%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.02%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.56%IOTAUSDT-3.87%AXSUSDT-2.36%FARTCOINUSDT-4.03%EOSUSDT-2.91%DYDXUSDT-2.49%ORDIUSDT-1.37%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.10%AAPL+2.69%GOOGL+0.24%MSFT+0.56%AMZN+0.12%TSM-0.81%SPCX+2.02%AVGO+0.03%META-0.22%TSLA-0.47%SKHY-3.57%MU-4.31%BRK-B-0.24%LLY+0.25%JPM-0.60%WMT+0.20%AMD-2.67%V-0.09%XOM+0.78%ASMLa-1.66%JNJ-0.19%INTC-4.47%MA-0.42%0700.HK-1.94%1398.HK+0.79%ORCL-2.97%ABBV+0.61%BAC-0.65%CSCO-0.91%CVX0.00%COST-0.01%KO+0.78%LRCX-4.62%CAT-1.46%AP2d-1.55%0005.HK-0.78%AMAT-2.16%UNH-0.23%HSBA.L-1.30%DELL-3.64%PG-0.05%MS-0.60%GE-0.47%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.05%HD-1.35%0939.HK+1.66%GS-0.76%NZDJPY-2.49%AUDJPY-1.75%CHFJPY-1.55%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.32%USDJPY-1.27%NZDUSD-1.25%EURJPY-1.20%GBPJPY-1.18%CADJPY-1.10%NZDCHF-0.97%USDZAR+0.89%USDNOK+0.82%EURZAR+0.79%USDSEK+0.77%AUDNZD+0.77%GBPZAR+0.74%EURNOK+0.72%AUDCAD-0.68%EURSEK+0.67%AUDDKK-0.60%CHFNOK+0.59%EURAUD+0.56%GBPAUD+0.55%USDTHB+0.54%CHFSEK+0.53%AUDUSD-0.49%AUDSGD-0.48%CADCHF+0.43%USDMXN+0.43%GBPTRY+0.41%NOKJPY-0.35%USDPLN+0.35%GBPCHF+0.35%EURCHF+0.34%GBPHKD+0.32%NZDSGD-0.31%USDCHF+0.29%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.25%USDSGD+0.21%AUDCHF-0.21%USDILS+0.16%USDCAD-0.15%AUDNOK+0.12%NZDMXN-0.12%PLNJPY+0.12%EURSGD+0.11%EURHKD-0.11%USDTRY+0.11%GBPCAD-0.10%USDDKK+0.10%EURCAD-0.10%EURCZK-0.08%USDCNH+0.08%GBPUSD+0.08%EURUSD+0.06%GBPSGD+0.06%USDCOP-0.04%CHFSGD-0.02%USDHKD+0.01%EURGBP+0.01%EURDKK0.00%EURCNH0.00%XPTUSD-5.22%UKOIL+4.94%USOIL+4.58%HG1-4.54%GAGUSD-4.20%XAGUSD-4.20%GAUUSD-0.80%XAUUSD-0.80%COTTON+0.67%S1+0.49%XNGUSD+0.48%COFFEE-0.46%BTCUSD-1.38%ETHUSD-0.57%USDTUSD-0.02%XRPUSD-2.75%SOLUSD-1.67%TRXUSDT+0.03%ZECUSDT-8.60%DOGEUSD-2.91%XMRUSDT-0.86%LINKUSD-1.49%XLMUSD-1.82%BCHUSDT-9.83%LTCUSD-1.56%UNIUSD-2.61%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.76%TAOUSDT-4.65%AAVEUSD-2.57%DOTUSDT-2.67%ICPUSDT-1.78%ONDOUSDT-3.23%WLDUSDT-2.67%ATOMUSDT-3.51%ARBUSDT-0.87%JUPUSDT-4.25%INJUSDT-3.68%STXUSDT-4.16%FETUSDT-3.86%TIAUSDT-1.65%PYTHUSDT-1.33%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.02%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.56%IOTAUSDT-3.87%AXSUSDT-2.36%FARTCOINUSDT-4.03%EOSUSDT-2.91%DYDXUSDT-2.49%ORDIUSDT-1.37%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
AB

Arbutus Biopharma Corp (ABUS)

NASDAQ • Healthcare

$5.17
-$0 (-0.2%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$5.16
Previous Close$5.17
Day Range$5.13 - $5.23
Avg. Volume (3M)4.9M
Market Cap$1B
P/E Ratio6.5
52 Week Range
$3.5$5.45
Next EarningsIn 67 daysNov 16, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1M100%
Gross Profitminus cost of goods$1M100%

Fundamentals & Financials

Revenue (TTM)
$181.7M
Net Income (TTM)
$153M
EPS (TTM)
$0.79
ROA (TTM)
55.85%
Current Ratio
81.42
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+71.5%Q1 2026-$0.01
+3000.0%Q2 2026$0.87
-50.0%Q3 2026-$0.03
Next

Nov 16

in 67 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Arbutus Biopharma Corp

Arbutus Biopharma Corp is a NASDAQ-listed biotechnology company that develops novel therapeutics for infectious disease, with its work centered on chronic hepatitis B. In FY2025, the company recorded $14.1 million in revenue. Its programs and supporting technology are based in the United States from Warminster, Pennsylvania.

Name
Arbutus Biopharma Corp
CEO
Lindsay Androski
Website
www.arbutusbio.com
Industry
Healthcare
Year Founded
2005
Employees
19

Today's Snapshot

AI-generated

ABUS is trading 1.1% lower at 5.12, while its sector was flat.

Trading Volume

Below 10d avg (3.8M)

871.8K

vs S&P 500 Today

Underperforming Market

-0.50%

Updated: September 10, 2026 at 16:40 UTC

ABUS Headlines

Arbutus plans US$230m share tender offer

August 21, 2026

3 min read
View All News

Technical Indicators

5 Buy3 Neutral0 Sell
ABUS shows a strong buy posture supported by trend strength, broad moving-average confirmation and healthy volume. ADX indicates a firm trend, RSI is above neutral, and the short, medium and long moving averages are all signaling buy, with the 200-day averages aligned beneath price. On-balance volume is strongly positive and MACD is slightly positive, while volatility is modest by ATR. The classic pivot sits near the current level and does not negate the bullish alignment. Technical takeaway: Strong Buy — widespread MA confirmation and positive volume underpin the uptrend.
All signals
  • EMA (5 indicators)$4.58 - $5.12
    Buy
  • RSI (14)60.58
    Neutral
  • Stochastic %K (14, 3, 3)50.98
    Neutral
  • MACD Level (12, 26)0.13
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24+5.7%
SEPNSepterna Inc
$37.97+1.6%
BCAXBicara Therapeutics Inc. Common Stock
$23.64-0.3%
SVRASavara Inc.
$5.42-2.0%
KURAKura Oncology, Inc.
$12.09-3.4%
SPRYARS Pharmaceuticals, Inc.
$5.23-3.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.